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Abstract
Background: Internet-administered cognitive behavioural therapy (ICBT) has been found to be effective for a
range of anxiety disorders. However, most studies have focused on one specific primary diagnosis and co-
morbidity has not been considered. In primary care settings, patients with anxiety often suffer from more than one
psychiatric condition, making it difficult to disseminate ICBT for specific conditions. The aim of this study will be to
investigate if ICBT tailored according to symptom profile can be a feasible treatment for primary care patients with
anxiety disorders. It is a randomised controlled trial aimed to evaluate the treatment against an active control
group.
Methods: Participants with anxiety disorders and co-morbid conditions (N = 128), will be recruited from a primary
care population. The Clinical Outcome in Routine Evaluation (CORE-OM) will serve as the primary outcome
measure. Secondary measures include self-reported depression, anxiety, quality of life and loss of production and
the use of health care. All assessments will be collected via the Internet and measure points will be baseline, post
treatment and 12 months post treatment.
Discussion: This trial will add to the body of knowledge on the effectiveness of ICBT for anxiety disorders in
primary care. The trial will also add knowledge on the long term effects of ICBT when delivered for regular clinic
patients
Trial Registration: ClinicalTrials.gov: NCT01390168
Keywords: Primary care, anxiety, depression, co-morbidity, Internet-administered cognitive behaviour therapy, cog-
nitive behaviour therapy
Background
Anxiety symptoms are one of the most common com-
plaints in mental health care [1]. In Europe, the 12-
month prevalence for any anxiety disorder is nearly 14
per cent [2,3]. When broadening the term to mental dis-
order, the number of people affected in the European
Union is 23.5 per cent [3], and co-morbidity rates are
high. The most common co-morbid disorder for people
with one anxiety disorder is mood disorders and other
anxiety disorders [4]. Although the number of people
suffering from mental disorders is high, only a small
number receive treatment [5], and a large number of
adult patients with anxiety disorders are treated in pri-
mary care settings and not in specialised care [6].
In an attempt to lower the barriers for help, Internet-
based cognitive behavioural therapy (ICBT) has been
shown to be effective [7]. ICBT can be, defined as:
“A therapy that is based on self-help books, guided by
an identified therapist, which gives feedback and
answers to questions, with a scheduling that mirrors
face-to-face treatment, and which can also include inter-
active online features such as queries to obtain pass-
words in order to get access to treatment modules” ([7]
p. 164).
This approach is different from pure self-help, in
which no feedback is given from the clinician. Including
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optimise outcomes [8-10]. ICBT has shown promising
results for a range of somatic and psychiatric conditions.
Research has shown similar outcomes as in face-to-face
therapy [11]. Moreover, there are several meta-analysis
showing promising results for anxiety disorders as well
as depression [10,12-14]. However, Coull and Morris
[15] found that even if guided self-help seems to have a
positive immediate effect, effectiveness at long-term fol-
low-up is considerably diminished. Furthermore, the
effects among clinically representative samples are lar-
gely unknown. In addition, most studies only target one
specific condition, leading to high exclusion rates, espe-
cially in media-recruited samples. If participants with
co-morbid disorders are included, the co-morbidity is
generally not targeted, since the Internet treatment
usually has manualised protocols leading to limited
opportunities for participants and therapists to influence
the treatment course. In face-to-face treatment, a beha-
viour analysis or a case conceptualisation is the starting
point, and a treatment plan is designed around the
information collected from the face-to-face appoint-
ment, by carrying out tailored treatments, these pro-
blems are addressed.
There is some evidence that tailored ICBT is a feasible
option in a heterogeneous self-recruited group of anxi-
ety participants [16]. In that study long-term treatment
benefits were found. There is some additional evidence
indicating that the effects of guided ICBT are main-
tained over longer time periods [17-19].
This study will consist of a sample referred via pri-
mary care contacts with the aim to test tailored ICBT in
an effectiveness study.
Methods/Design
Design
We will conduct a randomised controlled trial with two
conditions: (1) ICBT with scheduled guidance and (2)
an active waiting list control group: “attention control”.
The study has been approved by the regional Ethical
Board and has been registered in clinicaltrials.gov
(NCT01390168).
Study population
The study population will consist of adult primary care
patients fulfilling the DSM-IV-TR [20] criteria of any
specific anxiety disorder, or anxiety disorder not other-
wise specified. Hence, all participants must have clini-
cally significant symptoms. Co-morbidity will not serve
as a reason for exclusion, with the exception of health
conditions that will hinder participation in the study
and a few additional exclusion criteria. Participants will
be included regardless of co-occurring depression; how-
ever, the anxiety disorder will have to be the primary
diagnosis and complaint. Inclusion criteria will be the
following: the person must be 18 years of age or older;
they must have Internet access; they must be able to
take part in a telephone-administered diagnosis inter-
view; they should not be receiving any ongoing psycho-
logical treatment; and they should not be suffering from
clinical or sub-clinical anxiety symptoms, if the patient
is undergoing any medical treatment for their condition,
the dosage has to be stable for at least three months
prior to the start of the treatment. Participants with a
suicidal risk, defined as scoring 4 or higher on item 9 of
t h eM o n t g o m e r yÅ s b e r gR a t ing Scale-Self-rated
(MADRS-S [21]), and who are judged to show a high
risk in the SAD PERSONS [22] interview will be
excluded. Participants with ongoing alcohol dependence
will be excluded as well.
Sample size
Power calculations based on a moderate effect size of d
= 0.50, comparing the Clinical Outcomes in Routine
Evaluation-Outcome Measure (CORE-OM; [23]) scores
of the intervention group with the control group with a
two-sided t-test (alpha .05, power 80%). This is in accor-
dance with Chambless and Hollon’s [24] recommenda-
tions for empirically supported therapies. Hence, the N
will be set at 128 participants, with 64 in each arm.
Recruitment
Participants will be recruited from a clinical population-
typically by their physician when seeking help at their
primary care setting. Eligible participants will be given
an information folder containing brief information about
the trial and the link to the study website. On the web-
site they will find further information, an informed con-
sent form, a link to the questionnaires serving as
screening and the application for participation. The
informed consent form will be sent by surface post.
Randomisation and procedure
Initial selection will take place via computerised screen-
ing, consisting of the CORE-OM; [23], the self-rated
v e r s i o no ft h eM A D R S - S[ 2 5 ] ,B e c kA n x i e t yI n v e n t o r y
(BAI;[26]), Quality of Life Inventory (QOLI;[27]), and 10
additional questions regarding demographics and cur-
rent and past treatment. These results will later be used
as a pretreatment assessment.
Participants who fulfil the initial inclusion criteria,
according to the computerised screening, will be con-
tacted to take part in a telephone interview where they
will be interviewed using the Structured Clinical Inter-
view for DSM-IV-Axis I Disorders (SCID-I; [28]) by
seven MSc clinical psychology students trained in using
the interview. A psychiatrist and a clinical psychologist
will then assess the SCID protocols together with the
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clinical psychologist will subsequently tailor the treat-
ment according to each participant’su n i q u es e to fp r o -
blems and to some extent preferences. All participants
will be randomised by an online true random-number
service independent of the investigators and therapists.
The post-treatment assessment will take place 10 weeks
after the participants have started their treatment,
regardless of how many treatment modules have been
completed. There will also be a measurement at 12
months post treatment. All assessments, except the
diagnosis interview at pretreatment, are self-reported
and will be conducted via the Internet.
All communication will be administered via an online
messaging system resembling standard e-mailing sys-
tems connected to the study. All data is encrypted in
the database and a cryptographic protocol (Secure Sock-
ets Layer) will be used to provide communication secur-
ity over the Internet.
Intervention
Treatment
The treatment will cover a period of 10 weeks and con-
sist of a maximum of 10 modules, or chapters, per parti-
cipant. The modules are based on cognitive-behavioural
therapy (CBT) and shown to be effective when used on
specific diagnosed samples (i.e. panic disorder [29],
social phobia [30], GAD [19], depression [31]). Modules
will be rewritten to fit together in the tailored format (e.
g., words relating to specific conditions will be removed
like “panic disorder”).
Each module consists of a text (9-39 A4 pages) present-
ing a specific symptom (e.g. agoraphobia), exercises and
is completed by three to eight essay questions to be
worked through during a period of one week. Some of
the modules (i.e. relaxation and mindfulness) have audio
files attached to them for the participants to listen to.
The homework questions are intended to encourage
learning and to help the Internet therapist assess whether
the participants have assimilated the material or not. Par-
ticipants will be asked to answer the questions and pro-
vide worksheets and report on outcomes from different
exercises to their therapist and will then be served with
individual feedback. When the therapist receives a home-
work assignment showing that the participant has assimi-
lated the material, the next module will be made
accessible through an encrypted message exchange sys-
tem. If not posted in time, the therapist will send a
reminder message, and if the submitted homework does
not show adequate knowledge, the therapist will send
feedback to the participant regarding how to work on the
area further. Prescribed modules are available for down-
load in PDF format and participants will be advised to
print out the self-help material to make it easier to take
notes and to have the material readily available. The
therapists will be told not to spend more than 15 minutes
per participant per week in reading and communicating.
The first module (introduction) and the last (relapse
prevention) are fixed, which gives the clinician the possi-
bility to tailor the treatment by adding any of the follow-
ing: cognitive restructuring (2 modules), social anxiety (2
modules), generalised anxiety (3 modules), panic disorder
(2 modules), agoraphobia, behavioural activation (2 mod-
ules), applied relaxation, mindfulness, assertiveness, pro-
blem solving, stress management and sleep.
Attention control
Participants in the attention control group are asked
questions about their well-being on a weekly basis by
their therapist. Each participant will e-mail their answers
to the therapist once a week, but they are generally not
given any feedback on their answers.
Instruments
All questionnaires, except the diagnostic interview, will
be administered via the Internet. The reason for doing
this is to minimise the risk for keying errors and to be
cost-effective. Research has shown that Internet-admi-
nistered self-reporting of these questionnaires is as
equally valid as the paper and pencil versions [32,33].
The diagnostic interview (SCID-I) will be conducted by
telephone, a format shown to be as equally valid as face-
to-face administration [34].
All instruments will be used at pretreatment, post
treatment and at 12-month follow-up, with the excep-
tion of demographic data and diagnosis interview at
post treatment and in the long-term follow-up.
Demographic data
Ten background questions will be asked about age, gen-
der, education, past and previous treatment (both psy-
chological and medication) and employment status.
Diagnosis
The Structured Clinical Interview for DSM-IV-Axis I
disorders (SCID-I; [28]) will be used to investigate the
presence of a diagnosis. This is a semi-structured inter-
view to assess for DSM-IV Axis I-diagnoses.
Primary outcomes
The CORE-OM [23] is a 34-item scale covering four
subscales of subjective well-being. The scales are: symp-
toms (anxiety, depression, physical problems, trauma),
functioning (general functioning, close relationships,
social relationships) and risk (to self and others). Items
are scored from 0-4 and relate to the preceding week.
CORE-OM clinical scores can range from 0-40, with
higher scores indicating greater severity. Internal consis-
tency has been reported as a = .94 [23].
Secondary outcomes
For the measurement of anxiety symptoms, Beck Anxi-
ety Inventory (BAI; [26]) will be used. The BAI contains
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of 30 or higher is considered to correspond to severe
anxiety symptoms. Internal consistency is high [26],
with Cronbach’s alpha ranging from .90 to .94. and test-
retest reliability at r = .75.
Depressive symptoms will be measured using the
MADRS-S [25]. The scale consists of nine items rated
on a seven-grade scale measuring depressive symptoms
over the past three days. MADRS-S was developed to
measure changes in depressive symptoms and was ori-
ginally a clinical-rated version. The self-rated version
has shown a high degree of concordance with the clini-
cal-rated one [35]. Total scoring varies from 0-54, with
scores above 35 [36] considered as severe. This scale
will also serve as an initial indicator for suicidal risk
using the participants scoring on item 9 (suicidal
thoughts) as a marker for further investigation of the
matter. Concurrent validity is shown to be good with a
test-retest reliability of r = .83 [37].
As noted earlier, the use of MADRS-S and the scoring
on the suicidal thoughts item indicate the necessity for
further investigation on suicidality via a telephone-admi-
nistered interview conducted by a psychiatrist using the
SAD PERSONS scale [22]. The SAD PERSONS is an
acronym for 10 major risk factors (Sex, Age, Depression,
Previous attempt, Ethanol abuse, Rational thinking loss,
Social supports lacking, Organised plan, No spouse,
Sickness) and is used together with a clinical evaluation
carried out by the interviewer for assessing the likeli-
hood of suicidal attempts [22].
For the measurement of quality of life we will use the
QOLI [27]. This scale assesses subjective degree of satis-
faction in 16 different areas of life (e.g. health and
work). The scale show high internal consistency (a =
.77-.89), and a test-retest reliability from r =. 8 0t o. 9 1
[27].
For the measurement of loss of production and
health-care consumption the Trimbos and Institute of
Medical Technology Assessment Questionnaire on
Costs Associated with Psychiatric Illness (TiC-P; [38])
will be used. We will use part I (direct costs of health-
care consumption) and part II (indirect costs of loss of
production).
Analyses
When analysing post-treatment data and data collected
at one-year follow-up, an intention-to-treat design will
be used, to include all participants, regardless of their
compliance, withdrawal or protocol deviations. Between-
group changes at post treatment and at one-year-follow-
up will be calculated using analyses of covariance
(ANCOVAs), with pre-treatment scores as the covariate.
This approach is proven to be a reliable strategy in ana-
lysing the results of baseline and follow-up data in
RCTs [39]. Effect sizes between and within the two
groups will be calculated with Cohen’s d computed with
the pooled standard deviation.
Discussion
The trial described in this protocol is a randomised con-
trolled trial targeting individuals aged 18 years or older
who seek their primary care setting for emotional dis-
tress. The individuals suitable for this treatment will be
randomised into either treatment or an active control
group. Outcome measures post treatment will be com-
pared with those of the wait list control group. The pri-
mary aim is to assess the effectiveness of the tailored
online treatment both post treatment and at a one-year
follow-up.
Given the large number of individuals suffering from
mental disorders, and the small proportion receiving
adequate treatment for their condition, increasing the
accessibility of effective treatment is important. Given
that the bulk of patients fulfilling an anxiety diagnosis
suffer from at least one co-morbid disorder [4] makes it
important to investigate if the ICBT format of treatment
is applicable to these individuals as well. The main part
of earlier studies on ICBT has focused on only one pri-
mary diagnosis, leading to high exclusion rates of up to
84 per cent [29]. One of the aims of this study is to
investigate whether this kind of treatment could be fea-
sible for primary care patients regardless of anxiety diag-
nosis and co-morbidity, striving to test the effectiveness
of this treatment.
The recruitment of participants to this study is
designed to be similar to that of an ordinary process of
seeking psychological treatment via a primary care set-
ting. The patient and primary care contact will meet as
usual, as they would if they were receiving treatment,
and then the potential participant would be recom-
mended to apply for the study. This leaves their primary
care contact, in the first instance, to decide which treat-
ment to recommend for the patient’su n i q u es e to f
symptoms. This increases the external validity.
This design has some limitations. One possibility is
that the patients selected for the study will be consid-
ered being less severe patients-either by the characteris-
tics of their symptoms or by demographic
characteristics. Another limitation is the lack of control
group in the one-year follow-up. For ethical reasons, the
patients in our wait list will be offered the treatment
after 10 weeks. In terms of generalisation, it should be
taken into consideration that the sample could be
selected on other criteria than they would be if they
were receiving administered treatments. To reduce this
risk, close contact between the primary care settings
a n dt h ep r o j e c tl e a d e ro ft h es t u d yi ss t r i v e df o r .
Another fact is that the therapists in this study are
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psychologist or a counsellor that patients would nor-
mally meet in these settings. These issues are partly
being addressed by the fact that the students undergo
supervision from an experienced clinical psychologist.
Trial status
The trial is ongoing, still recruiting participants.
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